Table 2.
Multivariable model for predicting risk factors of survival in Ph+ ALL patients
| HR (95% CI) | p-value | |
|---|---|---|
| Progression-free survival | ||
| Current TKI therapy | 1.193 (0.397–3.590) | 0.753 |
| Concurrence of IKZF1 deletion | 2.514 (0.811–7.792) | 0.110 |
| MMAS-8 score | 0.639 (0.459–0.890) | 0.008 |
| Complex karyotype | 1.266 (0.490–3.269) | 0.626 |
| D19 MRD negative | 0.721 (0.281–1.847) | 0.495 |
| Days of TKIs interruption | 0.995 (0.979–1.012) | 0.585 |
| Overall survival | ||
| Current TKI therapy | 1.821 (0.562–5.902) | 0.318 |
| MMAS-8 score | 0.631 (0.418–0.954) | 0.029 |
| D19 MRD negative | 0.770 (0.254–2.333) | 0.644 |
| Days of TKIs interruption | 0.991 (0.971–1.012) | 0.416 |
| Dose reduction of TKIs | 0.373 (0.105–1.332) | 0.129 |
ALL, acute lymphoblastic leukemia; CI, confidence interval; HR, hazard ratio; MMAS-8, eight-item Morisky medication adherence scale; MRD, minimal residual disease; Ph+, chromosome-positive; TKI, tyrosine kinase inhibitor.